DrugPatentWatch Database Preview
Drugs in Development Information for PHA-793887
What is the development status for investigational drug PHA-793887?
PHA-793887 is an investigational drug.
There have been 28 clinical trials for PHA-793887.
The most recent clinical trial was a Phase 3 trial, which was initiated on January 1st 1999.
The most common disease conditions in clinical trials are Thymoma, HIV Infections, and Leukemia. The leading clinical trial sponsors are National Cancer Institute (NCI), Nerviano Medical Sciences, and Pfizer.
Summary for PHA-793887
| US Patents | 0 |
| International Patents | 0 |
| US Patent Applications | 5 |
| WIPO Patent Applications | 2 |
| Japanese Patent Applications | 0 |
| Clinical Trial Progress | Phase 3 (1999-01-01) |
| Vendors | 58 |
Recent Clinical Trials for PHA-793887
| Title | Sponsor | Phase |
|---|---|---|
| The Benefit of Bermekimab in Patients With Systemic Sclerosis | Hellenic Institute for the Study of Sepsis | Phase 2 |
| The Effects of Nanocurcumin on Serum miRNA and Th17 Cells Development Factors in Ankylosing Spondylitis Patients | Stem Cell and Regenerative Medicine Institute, Tabriz, Iran | Phase 2 |
| Recurrent Wheezing in Infants: Risk Factors and Prevention With Probiotics. | Conselho Nacional de Desenvolvimento Científico e Tecnológico | Phase 3 |
Clinical Trial Summary for PHA-793887
Top disease conditions for PHA-793887
Top clinical trial sponsors for PHA-793887
US Patents for PHA-793887
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
